Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report
Abstract Given the rarity of RAD51C mutations, the risk and treatment of metachronous breast cancer after the diagnosis of ovarian cancer in RAD51C mutation carriers is not clear, especially for those who have received PARPi treatment. We report the case of a 65-year-old woman diagnosed with stage I...
Main Authors: | Hua Yuan, Rong Zhang, Ning Li, Hongwen Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Hereditary Cancer in Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13053-024-00274-8 |
Similar Items
-
Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro
by: Yilin Dai, et al.
Published: (2024-01-01) -
Primary fallopian tube carcinoma: Preoperative diagnostic dilemma
by: Shalini Bhalla, et al.
Published: (2023-01-01) -
Recommendations for diagnosis, treatment and follow-up of patients with ovarian cancer, fallopian tube cancer and primary peritoneal cancer
by: Nina Kovačević, et al.
Published: (2022-11-01) -
Primary Fallopian Tube Cancer: An Unusual Case of Inguinal Lymphadenopathy
by: Zeinab Nazari, et al.
Published: (2019-07-01) -
Primary Fallopian Tube Carcinoma: An Extremely Rare Gynecological Cancer Misdiagnosed Intraoperatively as Benign Ovarian Neoplasm: A Case Report
by: Efthymia Thanasa, et al.
Published: (2022-04-01)